UPC
Universe Pharmaceuticals Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$2M
5Y Perf.-100.0%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
UPC vs XTLB vs SIGA vs NUVB
Revenue, margins, valuation, and 5-year total return — side by side.
XTLB
XTL Biopharmaceuticals Ltd.
Biotechnology
Market Cap$294K
5Y Perf.-80.0%
SIGA
SIGA Technologies, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$339M
5Y Perf.-27.2%
NUVB
Nuvation Bio Inc.
Biotechnology
Market Cap$1.67B
5Y Perf.-53.9%
UPC vs XTLB vs SIGA vs NUVB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | UPC | XTLB | SIGA | NUVB |
|---|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Market Cap | $2M | $294K | $339M | $1.67B |
| Revenue (TTM) | $41M | $451K | $94M | $143M |
| Net Income (TTM) | $-12M | $-1M | $-4.04T | $-146M |
| Gross Margin | 30.3% | 26.4% | 61.8% | 91.6% |
| Operating Margin | -26.7% | -481.6% | 27.7% | -105.0% |
| Forward P/E | — | — | 2.8x | — |
| Total Debt | $9M | $138K | $595K | $10M |
| Cash & Equiv. | $34M | $371K | $155M | $164M |
UPC vs XTLB vs SIGA vs NUVB — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
UPC
XTLB
SIGA
NUVB
| Stock | Mar 21 | May 26 | Return |
|---|---|---|---|
| Universe Pharmaceut… (UPC) | 100 | 0.0 | -100.0% |
| XTL Biopharmaceutic… (XTLB) | 100 | 20.0 | -80.0% |
| SIGA Technologies, … (SIGA) | 100 | 72.8 | -27.2% |
| Nuvation Bio Inc. (NUVB) | 100 | 46.1 | -53.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: UPC vs XTLB vs SIGA vs NUVB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SIGA leads in 3 of 6 categories, making it the strongest pick for capital preservation and lower volatility and dividend income and shareholder returns. Nuvation Bio Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. UPC also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
UPC
Universe Pharmaceuticals Inc.
The Quality Compounder
UPC is the clearest fit if your priority is quality.
- -30.3% margin vs SIGA's -43K%
Best for: quality
XTLB
XTL Biopharmaceuticals Ltd.
The Secondary Option
XTLB lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
SIGA
SIGA Technologies, Inc.
The Income Pick
SIGA carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 4 yrs, beta 1.15, yield 12.7%
- 7.6% 10Y total return vs NUVB's -51.8%
- Lower volatility, beta 1.15, Low D/E 0.3%, current ratio 11.83x
- Beta 1.15, yield 12.7%, current ratio 11.83x
Best for: income & stability and long-term compounding
NUVB
Nuvation Bio Inc.
The Growth Play
NUVB is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 7.0%, EPS growth 71.6%
- 7.0% revenue growth vs XTLB's -173.2%
- +136.3% vs XTLB's -50.9%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NUVB | 7.0% revenue growth vs XTLB's -173.2% |
| Quality / Margins | UPC | -30.3% margin vs SIGA's -43K% |
| Stability / Safety | SIGA | Beta 1.15 vs NUVB's 2.04, lower leverage |
| Dividends | SIGA | 12.7% yield; 4-year raise streak; the other 3 pay no meaningful dividend |
| Momentum (1Y) | NUVB | +136.3% vs XTLB's -50.9% |
| Efficiency (ROA) | SIGA | -7.4% ROA vs NUVB's -23.8%, ROIC 33.7% vs -54.3% |
UPC vs XTLB vs SIGA vs NUVB — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
FY 2025
FY 2025
UPC vs XTLB vs SIGA vs NUVB — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSIGALAGGINGXTLB
Who Leads Where
NUVB leads in 2 of 6 categories
SIGA leads 2 • UPC leads 1 • XTLB leads 0 • 1 tied
Explore the data ↓XTLBXTL Biopharmaceutical…
0leads
UPCUniverse Pharmaceutic…
1leads
NUVBNuvation Bio Inc.
2leads
SIGASIGA Technologies, In…
2leads
6 Total Categories
CATEGORYLEADERvs NUVBvs UPCMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
NUVB3/6
Valuation MetricsMultiples, price ratios, and targets
UPC2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SIGA7/9
Total Returns1Y, 3Y, 5Y total returns with dividends
NUVB3/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
SIGA1/1
Income & Cash Flow (Last 12 Months)
NUVB leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NUVB is the larger business by revenue, generating $143M annually — 317.2x XTLB's $451,000. UPC is the more profitable business, keeping -30.3% of every revenue dollar as net income compared to SIGA's -43117.4%. On growth, NUVB holds the edge at +26.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | UPCUniverse Pharmace… | XTLBXTL Biopharmaceut… | SIGASIGA Technologies… | NUVBNuvation Bio Inc. |
|---|---|---|---|---|
| RevenueTrailing 12 months | $41M | $451,000 | $94M | $143M |
| EBITDAEarnings before interest/tax | -$10M | -$1M | $26M | -$145M |
| Net IncomeAfter-tax profit | -$12M | -$1M | -$4.04T | -$146M |
| Free Cash FlowCash after capex | -$15M | $0 | $33M | -$126M |
| Gross MarginGross profit ÷ Revenue | +30.3% | +26.4% | +61.8% | +91.6% |
| Operating MarginEBIT ÷ Revenue | -26.7% | -4.8% | +27.7% | -105.0% |
| Net MarginNet income ÷ Revenue | -30.3% | -2.3% | -43117.4% | -102.1% |
| FCF MarginFCF ÷ Revenue | -37.2% | -3.7% | +35.2% | -88.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -14.1% | — | -11.3% | +26.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -100.1% | +20.0% | — | +106.3% |
NUVB leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
UPC leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | UPCUniverse Pharmace… | XTLBXTL Biopharmaceut… | SIGASIGA Technologies… | NUVBNuvation Bio Inc. |
|---|---|---|---|---|
| Market CapShares × price | $2M | $293,767 | $339M | $1.7B |
| Enterprise ValueMkt cap + debt − cash | -$23M | $60,767 | $185M | $1.5B |
| Trailing P/EPrice ÷ TTM EPS | -0.00x | -0.28x | 14.33x | -8.03x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 2.78x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | 7.60x | — |
| Price / SalesMarket cap ÷ Revenue | 0.09x | 0.65x | 3.58x | 26.61x |
| Price / BookPrice ÷ Book value/share | 0.00x | 0.05x | 1.70x | 5.38x |
| Price / FCFMarket cap ÷ FCF | — | — | 6.96x | — |
UPC leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
SIGA leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
SIGA delivers a -10.7% return on equity — every $100 of shareholder capital generates $-11 in annual profit, vs $-44 for NUVB. SIGA carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to UPC's 0.16x. On the Piotroski fundamental quality scale (0–9), SIGA scores 5/9 vs XTLB's 3/9, reflecting solid financial health.
| Metric | UPCUniverse Pharmace… | XTLBXTL Biopharmaceut… | SIGASIGA Technologies… | NUVBNuvation Bio Inc. |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -27.0% | -25.5% | -10.7% | -44.1% |
| ROA (TTM)Return on assets | -18.6% | -17.7% | -7.4% | -23.8% |
| ROICReturn on invested capital | -7.8% | -54.1% | +33.7% | -54.3% |
| ROCEReturn on capital employed | -5.6% | -50.7% | +11.3% | -42.8% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.16x | 0.03x | 0.00x | 0.03x |
| Net DebtTotal debt minus cash | -$24M | -$233,000 | -$154M | -$154M |
| Cash & Equiv.Liquid assets | $34M | $371,000 | $155M | $164M |
| Total DebtShort + long-term debt | $9M | $138,000 | $595,169 | $10M |
| Interest CoverageEBIT ÷ Interest expense | -22.11x | -13.31x | — | -162.11x |
SIGA leads this category, winning 7 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
NUVB leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SIGA five years ago would be worth $10,136 today (with dividends reinvested), compared to $3 for UPC. Over the past 12 months, NUVB leads with a +136.3% total return vs XTLB's -50.9%. The 3-year compound annual growth rate (CAGR) favors NUVB at 43.8% vs UPC's -89.3% — a key indicator of consistent wealth creation.
| Metric | UPCUniverse Pharmace… | XTLBXTL Biopharmaceut… | SIGASIGA Technologies… | NUVBNuvation Bio Inc. |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -27.9% | +11.3% | -15.0% | -43.8% |
| 1-Year ReturnPast 12 months | -41.1% | -50.9% | +1.5% | +136.3% |
| 3-Year ReturnCumulative with dividends | -99.9% | -45.7% | +22.2% | +197.5% |
| 5-Year ReturnCumulative with dividends | -100.0% | -80.4% | +1.4% | -58.3% |
| 10-Year ReturnCumulative with dividends | -100.0% | -87.3% | +764.0% | -51.8% |
| CAGR (3Y)Annualised 3-year return | -89.3% | -18.4% | +6.9% | +43.8% |
NUVB leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — SIGA and NUVB each lead in 1 of 2 comparable metrics.
Risk & Volatility
SIGA is the less volatile stock with a 1.15 beta — it tends to amplify market swings less than NUVB's 2.04 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NUVB currently trades 49.4% from its 52-week high vs XTLB's 26.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | UPCUniverse Pharmace… | XTLBXTL Biopharmaceut… | SIGASIGA Technologies… | NUVBNuvation Bio Inc. |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.26x | 1.71x | 1.15x | 2.04x |
| 52-Week HighHighest price in past year | $11.00 | $10.28 | $9.62 | $9.75 |
| 52-Week LowLowest price in past year | $2.00 | $1.05 | $4.29 | $1.57 |
| % of 52W HighCurrent price vs 52-week peak | +27.3% | +26.0% | +49.2% | +49.4% |
| RSI (14)Momentum oscillator 0–100 | 41.9 | 57.0 | 47.0 | 59.1 |
| Avg Volume (50D)Average daily shares traded | 8K | 2.4M | 688K | 4.3M |
Evenly matched — SIGA and NUVB each lead in 1 of 2 comparable metrics.
Analyst Outlook
SIGA leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: SIGA as "Buy", NUVB as "Buy". SIGA is the only dividend payer here at 12.73% yield — a key consideration for income-focused portfolios.
| Metric | UPCUniverse Pharmace… | XTLBXTL Biopharmaceut… | SIGASIGA Technologies… | NUVBNuvation Bio Inc. |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | Buy | Buy |
| Price TargetConsensus 12-month target | — | — | — | $12.40 |
| # AnalystsCovering analysts | — | — | 1 | 9 |
| Dividend YieldAnnual dividend ÷ price | — | — | +12.7% | — |
| Dividend StreakConsecutive years of raises | 2 | — | 4 | — |
| Dividend / ShareAnnual DPS | — | — | $0.60 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
SIGA leads this category, winning 1 of 1 comparable metric.
Key Takeaway
NUVB leads in 2 of 6 categories (Income & Cash Flow, Total Returns). SIGA leads in 2 (Profitability & Efficiency, Analyst Outlook). 1 tied.
Best OverallSIGA Technologies, Inc. (SIGA)Leads 2 of 6 categories
Loading custom metrics...
UPC vs XTLB vs SIGA vs NUVB: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is UPC or XTLB or SIGA or NUVB a better buy right now?
For growth investors, Nuvation Bio Inc.
(NUVB) is the stronger pick with 699. 0% revenue growth year-over-year, versus -31. 8% for SIGA Technologies, Inc. (SIGA). SIGA Technologies, Inc. (SIGA) offers the better valuation at 14. 3x trailing P/E (2. 8x forward), making it the more compelling value choice. Analysts rate SIGA Technologies, Inc. (SIGA) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — UPC or XTLB or SIGA or NUVB?
Over the past 5 years, SIGA Technologies, Inc.
(SIGA) delivered a total return of +1. 4%, compared to -100. 0% for Universe Pharmaceuticals Inc. (UPC). Over 10 years, the gap is even starker: SIGA returned +764. 0% versus UPC's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — UPC or XTLB or SIGA or NUVB?
By beta (market sensitivity over 5 years), SIGA Technologies, Inc.
(SIGA) is the lower-risk stock at 1. 15β versus Nuvation Bio Inc. 's 2. 04β — meaning NUVB is approximately 77% more volatile than SIGA relative to the S&P 500. On balance sheet safety, SIGA Technologies, Inc. (SIGA) carries a lower debt/equity ratio of 0% versus 16% for Universe Pharmaceuticals Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — UPC or XTLB or SIGA or NUVB?
By revenue growth (latest reported year), Nuvation Bio Inc.
(NUVB) is pulling ahead at 699. 0% versus -31. 8% for SIGA Technologies, Inc. (SIGA). On earnings-per-share growth, the picture is similar: Nuvation Bio Inc. grew EPS 71. 6% year-over-year, compared to -60. 2% for SIGA Technologies, Inc.. Over a 3-year CAGR, SIGA leads at -5. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — UPC or XTLB or SIGA or NUVB?
SIGA Technologies, Inc.
(SIGA) is the more profitable company, earning 24. 6% net margin versus -325. 3% for Nuvation Bio Inc. — meaning it keeps 24. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SIGA leads at 25. 1% versus -481. 6% for XTLB. At the gross margin level — before operating expenses — NUVB leads at 86. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — UPC or XTLB or SIGA or NUVB?
In this comparison, SIGA (12.
7% yield) pays a dividend. UPC, XTLB, NUVB do not pay a meaningful dividend and should not be held primarily for income.
07Is UPC or XTLB or SIGA or NUVB better for a retirement portfolio?
For long-horizon retirement investors, SIGA Technologies, Inc.
(SIGA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15), 12. 7% yield, +764. 0% 10Y return). Nuvation Bio Inc. (NUVB) carries a higher beta of 2. 04 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SIGA: +764. 0%, NUVB: -51. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between UPC and XTLB and SIGA and NUVB?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: UPC is a small-cap quality compounder stock; XTLB is a small-cap quality compounder stock; SIGA is a small-cap deep-value stock; NUVB is a small-cap high-growth stock. SIGA pays a dividend while UPC, XTLB, NUVB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.